Glucose Metabolism Disorders  >>  Invokana (canagliflozin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
NCT02053116: A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

Terminated
2a
8
US
PF-05175157, Placebo
Pfizer
Type 2 Diabetes Mellitus
04/14
04/14
NCT00642278: An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Checkmark P2 data
May 2012 - May 2012: P2 data
Completed
2
451
US, Canada, Europe, RoW
Canagliflozin (JNJ-28431754), JNJ-28431754, Sitagliptin, Placebo
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
01/09
01/09
NCT01022112: An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes

Checkmark
Jun 2013 - Jun 2013: 
Completed
2
383
Japan
TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle, TA-7284-High, Placebo
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
09/10
09/10
NCT01340664 / 2010-024256-28: An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Completed
2
279
US, Canada, Europe, RoW
Canagliflozin 50 mg, Placebo, Canagliflozin 150 mg, Metformin
Janssen Research & Development, LLC
Diabetes Mellitus, Type 2
04/12
04/12
NCT02139943: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Completed
2
352
US, Canada
Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
Janssen Research & Development, LLC
Diabetes Mellitus, Type 1
06/15
06/15
NCT00707954: Safety, Pharmacokinetics and Pharmacodynamics of TA-7284 in Type 2 Diabetic Patients

Completed
1/2
61
Japan
TA-7284, Placebo of TA-7284
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
02/09
02/09

Download Options